CA
NZ
UK
AU
IND
US
● Details were thin on Thursday night, and the gap to expectations was not verified.
● The baseBusinessoutlook was raised for the third time this year.
● The 2026 sales outlook was raised to a range of $775 million to $785 million.
● Management raised 2026 sales guidance to $775 million to $785 million.
● Management expects to land in the upper half of its 2026 guidance ranges.
● The company guided 2026 revenue to $4.64 billion to $4.66 billion.
● Insmed raised the low end of 2026 Brinsupri guidance to $1.35 billion.
● The low end of 2026 Brinsupri guidance rose to $1.35 billion.
● Seventeen of those patients had an objective response to treatment.
● Mesoblast's American depositary shares climbed to $15.63 among theNasdaqComposite's biggest gainers.
Please wait processing your request...